Global and Regional Projections of the Economic Burden of Alzheimer's Disease and Related Dementias from 2019 to 2050: A Value of Statistical Life Approach

Overview

Journal EClinicalMedicine

Specialty General Medicine

Date 2022 Jul 28

PMID 35898316

Authors

Arindam Nandi

Nathaniel Counts

Simiao Chen

Benjamin Seligman

Daniel Tortorice

Daniel Vigo

David E Bloom

Affiliations

Soon will be listed here.

Abstract

Background: The burden of Alzheimer's disease and related dementias (ADRDs) is expected to grow rapidly with population aging, especially in low- and middle-income countries, in the next few decades. We used a willingness-to-pay approach to project the global, regional, and national economic burden of ADRDs from 2019 to 2050 under status quo.

Methods: We projected age group and country-specific disability-adjusted life years (DALYs) lost to ADRDs in future years based on historical growth in disease burden and available population projections. We used country-specific extrapolations of the value of a statistical life (VSL) year and its future projections based on historical income growth to estimate the economic burden - measured in terms of the value of lost DALYs - of ADRDs. A probabilistic uncertainty analysis was used to calculate point estimates and 95% uncertainty bounds of the economic burden.

Findings: In 2019, the global VSL-based economic burden of ADRDs was an estimated $2.8 trillion. The burden was projected to increase to $4.7 trillion (95% uncertainty bound: $4 trillion-$5.5 trillion) in 2030, $8.5 trillion ($6.8 trillion-$10.8 trillion) in 2040, and $16.9 trillion ($11.3 trillion-$27.3 trillion) in 2050. Low- and middle-income countries (LMICs) would account for 65% of the global VSL-based economic burden in 2050, as compared with only 18% in 2019. Within LMICs, upper-middle income countries would carry the largest VSL-based economic burden by 2050 (92% of LMICs burden and 60% of global burden).

Interpretation: ADRDs have a large and inequitable projected future VSL-based economic burden.

Funding: The Davos Alzheimer's Collaborative.

Citing Articles

Annual societal cost of Alzheimer's disease in Malaysia: a micro-costing approach.

Ong S, Tay L, Ong H, Tiong I, Chng A, Parumasivam T BMC Geriatr. 2025; 25(1):154.

PMID: 40050715 PMC: 11884180. DOI: 10.1186/s12877-025-05717-y.

Natural language processing of electronic health records for early detection of cognitive decline: a systematic review.

Shankar R, Bundele A, Mukhopadhyay A NPJ Digit Med. 2025; 8(1):133.

PMID: 40025194 PMC: 11873039. DOI: 10.1038/s41746-025-01527-z.

Trends of the Dementia Burden in South Asia: An Analysis of 2021 Global Burden of Disease Study.

Chauhan S, Jena D, Gaidhane S, Dev N, Bushi G, Priya G Aging Med (Milton). 2025; 8(1):e70002.

PMID: 40017668 PMC: 11865018. DOI: 10.1002/agm2.70002.

Long-Term Insomnia Treatment with Benzodiazepines and Alzheimer's Disease: A Systematic Review.

Trigo F, Pinto N, Pato M NeuroSci. 2025; 6(1).

PMID: 39982263 PMC: 11843827. DOI: 10.3390/neurosci6010011.

Association between pain and behavioral and psychological symptoms of dementia (BPSD) in older adults with dementia: a systematic review and meta-analysis.

Shi T, Xu Y, Li Q, Zhu L, Jia H, Qian K BMC Geriatr. 2025; 25(1):100.

PMID: 39953384 PMC: 11829437. DOI: 10.1186/s12877-025-05719-w.

References

Robinson L, Hammitt J, OKeeffe L . Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis. J Benefit Cost Anal. 2020; 10(Suppl 1):15-50. PMC: 7473065. DOI: 10.1017/bca.2018.26. View

Haagsma J, Polinder S, Cassini A, Colzani E, Havelaar A . Review of disability weight studies: comparison of methodological choices and values. Popul Health Metr. 2015; 12:20. PMC: 4445691. DOI: 10.1186/s12963-014-0020-2. View

Alkire B, Hughes C, Nash K, Vincent J, Meara J . Potential economic benefit of cleft lip and palate repair in sub-Saharan Africa. World J Surg. 2011; 35(6):1194-201. DOI: 10.1007/s00268-011-1055-1. View

Robinson L, Hammitt J, Jamison D, Walker D . Conducting Benefit-Cost Analysis in Low- and Middle-Income Countries: Introduction to the Special Issue. J Benefit Cost Anal. 2020; 10(Suppl 1):1-14. PMC: 7672367. DOI: 10.1017/bca.2019.4. View

Ranjeva S, Warf B, Schiff S . Economic burden of neonatal sepsis in sub-Saharan Africa. BMJ Glob Health. 2018; 3(1):e000347. PMC: 5859806. DOI: 10.1136/bmjgh-2017-000347. View

. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022; 7(2):e105-e125. PMC: 8810394. DOI: 10.1016/S2468-2667(21)00249-8. View

Hurd M, Martorell P, Langa K . Future Monetary Costs of Dementia in the United States under Alternative Dementia Prevalence Scenarios. J Popul Ageing. 2015; 8(1-2):101-112. PMC: 4410878. DOI: 10.1007/s12062-015-9112-4. View

Corlew D, Alkire B, Poenaru D, Meara J, Shrime M . Economic valuation of the impact of a large surgical charity using the value of lost welfare approach. BMJ Glob Health. 2017; 1(4):e000059. PMC: 5321371. DOI: 10.1136/bmjgh-2016-000059. View

Yin H, Brauer M, Zhang J, Cai W, Navrud S, Burnett R . Population ageing and deaths attributable to ambient PM pollution: a global analysis of economic cost. Lancet Planet Health. 2021; 5(6):e356-e367. DOI: 10.1016/S2542-5196(21)00131-5. View

10.

Hammitt J . Valuing mortality risk in the time of COVID-19. J Risk Uncertain. 2020; 61(2):129-154. PMC: 7656098. DOI: 10.1007/s11166-020-09338-1. View

11.

Viscusi W . Economic lessons for COVID-19 pandemic policies. South Econ J. 2021; 87(4):1064-1089. PMC: 8013555. DOI: 10.1002/soej.12492. View

12.

Morgan A, Hartmanis S, Tsochatzis E, Newsome P, Ryder S, Elliott R . Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ. 2021; 22(4):505-518. PMC: 8166804. DOI: 10.1007/s10198-020-01256-y. View

13.

Pedroza Velandia P, Miller-Petrie M, Chen C, Chakrabarti S, Chapin A, Hay S . Global and regional spending on dementia care from 2000-2019 and expected future health spending scenarios from 2020-2050: An economic modelling exercise. EClinicalMedicine. 2022; 45:101337. PMC: 8921543. DOI: 10.1016/j.eclinm.2022.101337. View

14.

Langa K, Plassman B, Wallace R, Herzog A, Heeringa S, Ofstedal M . The Aging, Demographics, and Memory Study: study design and methods. Neuroepidemiology. 2005; 25(4):181-91. DOI: 10.1159/000087448. View

15.

Watts E, Sim S, Constenla D, Sriudomporn S, Brenzel L, Patenaude B . Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches. Value Health. 2021; 24(1):78-85. DOI: 10.1016/j.jval.2020.07.009. View

16.

Ballarini T, van Lent D, Brunner J, Schroder A, Wolfsgruber S, Altenstein S . Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age. Neurology. 2021; 96(24):e2920-e2932. PMC: 8253566. DOI: 10.1212/WNL.0000000000012067. View

17.

Jia J, Wei C, Chen S, Li F, Tang Y, Qin W . The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018; 14(4):483-491. DOI: 10.1016/j.jalz.2017.12.006. View

18.

Wimo A, Guerchet M, Ali G, Wu Y, Prina A, Winblad B . The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2016; 13(1):1-7. PMC: 5232417. DOI: 10.1016/j.jalz.2016.07.150. View

19.

ODonohoe T, Choudhury A, Callander E . Global macroeconomic burden of epilepsy and the role for neurosurgery: a modelling study based upon the 2016 Global Burden of Disease data. Eur J Neurol. 2019; 27(2):360-368. DOI: 10.1111/ene.14085. View

20.

El-Hayek Y, Wiley R, Khoury C, Daya R, Ballard C, Evans A . Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. J Alzheimers Dis. 2019; 70(2):323-341. PMC: 6700654. DOI: 10.3233/JAD-190426. View